NEP

N-Ethylpentedrone

Ethyl-pentedrone, N-ethylnorpentedrone, α-ethylaminopentiophenone, α-EAPP, α-ethylamino-valerophenone

Psychoactive Class

Chemical Class

NEP is a substituted cathinone¹ that produces stimulating, euphoric, and mildly entactogenic effects. It first appeared on the research chemical market in 2016 as a contemporary designer drug. Structurally related to pentedrone, it differs by an additional ethyl group on the terminal nitrogen, reportedly making it roughly three times as potent.² NEP is also closely related to N-ethylhexedrone and is noted for its relatively short duration of action.²

Dosage & Duration

Dosage

Threshold~10 mg

Light10-20 mg

Moderate20-40 mg

Strong40-60 mg

Heavy60+ mg

Duration

Onset10-20 minutes

After Effects1-24 hours

Total2.5-4 hours

Subjective Effects

NEP produces a short-acting stimulant experience centered on wakefulness, modest mood enhancement, talkativeness, and restless energy, with a headspace that tends to be scattered rather than focused. Rapid-onset routes can produce a brief euphoric rush, but it is generally weak and subsides within five to ten minutes, and many users experience little more than a fast surge of energy. The most enjoyable effects last roughly 45 to 60 minutes before giving way to plain stimulation, and because euphoria fades faster than the stimulation itself — often declining within two to three doses — the substance is strongly associated with compulsive redosing and extended binges. A small minority of users describe mildly entactogen-like warmth, though far below the intensity of substances like MDMA.

Physical

Stimulation at common doses is described as relatively smooth with minimal bodyload. Heavier use frequently brings a racing or pounding heart, palpitations, restlessness, muscle tension, jaw clenching, and cold extremities from vasoconstriction. Insufflation causes nasal pain and irritation that ranges from a few minutes of burning to severe inflammation, persistent sneezing, and occasional bleeding depending on the batch and level of use.

Cardiovascular

Cardiovascular effects are minor at common doses but become prominent with heavier use.

Increased blood pressure

Stimulation

Uncomfortable

Insufflation is inconsistently but sometimes severely irritating, ranging from brief burning to intense pain, inflammation, persistent sneezing for 30-60 minutes, and nose bleeding depending on the batch.

Dry mouth Constipation Difficulty urinating

Cognitive

The headspace is energetic and talkative but characteristically scatterbrained, with frequent task-switching that undermines its functional potential; clearheaded mental work is usually impaired even at lower doses. Anxiety is absent or mild at common doses but escalates sharply with large doses and prolonged redosing, potentially progressing to paranoia, delusions, or psychosis when combined with multiday binges and sleep deprivation.

Emotional

Minor to moderate mood enhancement is more common than true euphoria, and the emotional tone deteriorates quickly with redosing and heavy use.

Enhancements

Psychosis

Psychotic effects are associated with large amounts over multiday periods combined with severe sleep deprivation, and appear to onset faster than with classic stimulants.

Suppressions

Visual

Visual effects are essentially absent at common doses and emerge primarily as impairments during heavy use, binges, and sleep deprivation.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

NEP is believed to act primarily as a norepinephrine-dopamine reuptake inhibitor, increasing the accumulation of these monoamines in the brain.³ One study has characterized it as a serotonin-norepinephrine-dopamine reuptake inhibitor with very poor affinity for the serotonin transporter, suggesting that its activity is heavily biased toward dopamine and norepinephrine.⁴ The structurally similar cathinone pentedrone has been shown to function as a reuptake inhibitor rather than a monoamine releaser, which may also apply to NEP, though interactions with additional receptor sites have not been ruled out.⁵

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

5-HTPAlcoholCocaineDXMDissociativesMAOIsMDMAMXENBOMe compoundsSNRIsSSRIsSerotonin releasersStimulantsTramadol

TripSit

Tolerance

Full Tolerance

With sustained repeated NEP use, tolerance may develop across many effects. Euphoria can begin declining within 2-3 doses, and continued use may mainly extend wakefulness and intoxication while positive effects become shorter and weaker.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

Dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

Moderately addictive with a high potential for abuse and capable of causing psychological dependence.⁶ Compulsive redosing is a common pattern, with users entering an almost automatic state of redosing regardless of whether the effects remain pleasant. The short duration contributes to repeated administration, and once use deviates from planned limits, escalation is common.

Physical

Low

When addiction has developed, cravings and withdrawal effects may occur upon cessation. Physical dependence appears less prominent than psychological dependence, with sources primarily emphasizing compulsive use patterns rather than severe physical withdrawal.

Toxicity

Cardiovascular

Increases heart rate significantly compared to other stimulants, even at low doses, along with elevated blood pressure and occasional abnormal heartbeat;² acute myocardial infarction, arrhythmias, and stroke are presumed possible with large overdoses, though no formal data exists.

Nasal/Respiratory

Intranasal use causes nasal discomfort and irritation; heavy use can produce significant nasal inflammation and occasionally bleeding, though severity varies substantially between batches.

Psychosis Risk

Extended use at high dosages can result in stimulant psychosis presenting with paranoia, hallucinations, and delusions.⁷ Compared to classic stimulants, paranoia, visual distortions, and unusual thinking appear to have faster onset, potentially becoming apparent within one day of heavy use. Sleep deprivation significantly increases risk. The most concerning effects can almost always be prevented by avoiding sleep deprivation and limiting use duration.

Seizure Risk

No case reports of NEP-induced seizures exist, but like other stimulants it likely has seizure-inducing capacity. Best avoided in those with preexisting seizure disorders.

History & Culture

N-Ethylpentedrone emerged on the online research chemical market during the mid-2010s, with documented user experience reports beginning to appear around 2016. The compound represents a generation of synthetic cathinone derivatives developed as functional and structural alternatives to earlier…

Legality

By Country

United StatesNot scheduled

Not federally scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption could potentially be prosecuted under the Federal Analogue Act due to structural and pharmacological similarities to pentedrone, which is a Schedule I controlled substance.¹⁷

BrazilControlled

All cathinone analogues became controlled substances on September 7, 2018, through a blanket ban appended to Portaria SVS/MS nº 344. Possession, use, and distribution are illegal.⁹

ChinaControlled

Listed as a controlled substance under national drug legislation. Production, distribution, and possession without authorization are prohibited.

GermanyNpSG controlled

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.¹² Production and importation for market distribution, administration to others, and trading are punishable offenses.¹³ Possession is illegal but not subject to criminal penalties.

JapanControlled

Designated as a controlled substance under national drug control legislation. Possession, distribution, and manufacturing are prohibited.

SwedenControlled

Classified as a controlled substance since November 12, 2019. Subject to Swedish narcotics legislation with penalties for possession, distribution, and manufacturing.

United KingdomClass B

Controlled as a Class B substance under the Misuse of Drugs Act 1971 through a cathinone catch-all clause.¹⁶ Possession carries penalties of up to five years imprisonment, while supply offenses carry up to fourteen years.

AustraliaSchedule 9

Prohibited substance under a cathinone blanket ban provision. As a Schedule 9 substance, no therapeutic use is recognized and possession, production, and distribution are illegal.

CanadaNot explicitly scheduled

While not individually listed, NEP may be treated as a Schedule I substance under the Controlled Drugs and Substances Act due to provisions banning derivatives of amphetamine.¹⁰

FranceStupéfiant

Classified as a narcotic substance (stupéfiant) as a derivative of cathinone with alkyl substitutions on the nitrogen and R2 position.¹¹ Possession, purchase, sale, and manufacture are illegal.

ItalyTable 1

Added to Table 1 of psychotropic substances on December 29, 2020.¹⁴ As a Table 1 substance, it is subject to the strictest controls under Italian drug legislation.

NetherlandsLegal

Currently unscheduled and legal to possess. However, it belongs to a substance group that may become prohibited under recently enacted New Psychoactive Substances (NPS) legislation.¹⁵

SwitzerlandControlled (Verzeichnis E)

Regulated as a defined derivative of cathinone under Verzeichnis E point 1 of the narcotics legislation. An exception exists for scientific or industrial purposes, which remain legal with appropriate authorization.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the NEP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

NEP

N-Ethylpentedrone

Ethyl-pentedrone, N-ethylnorpentedrone, α-ethylaminopentiophenone, α-EAPP, α-ethylamino-valerophenone

Psychoactive Class

Stimulant Entactogen (mild)

Chemical Class

Cathinone (substituted)